DiscGenics’ proprietary Discogenic cells will be assessed in use with the VA’s whole, tissue-engineered endplate-modified disc-like angle ply structure, called eDAPS. They are living tissue-engineered resorbable polymer vertebral disc implants mimicking natural disc function and structure.
The eDAPS are designed to replace degenerated discs for patients with late-stage intervertebral disc degeneration.
“A biologic disc replacement in lieu of existing mechanical devices would continue to change the paradigm of spine care away from a device-centric model to one of disease modification through biologic and cell-based treatments,” Kevin Foley, MD, chief medical officer of DiscGenics, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.